This isn’t IdentifySensors Biologics’s most recent raise. Reg CF · Common Stock · Jan 2024 (Closed) is more current.View latest round

Reg A+ · Equity · Jul 2023

ClosedReg A+Equity

via DALMORE GROUP LLC · last checked Aug 16, 2026

Raised

$0 / $50M max

0% of ceiling

Investors

—

Estimated pre-money

$209M

—

Financials disclosed in this offering

FY2022 · hover for source

−$3.1M

FY2022

RevenueNet income

Metric

FY2022 audited

Income statement

Revenue

Cost of goods sold

Net income

-$3,061,059

Taxes paid

Balance sheet

Cash

$1,995,851

Accounts receivable

Total assets

$2,157,634

Short-term debt

$1,886,215

Long-term debt

$230,265

Total liabilities

$1,163,465

Other

Headcount

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

1 amendment

Nov 22, 2023
Terms not yet extracted from this filing
Form 1-A/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. Form 1-A amendments state no reason; those filed before qualification are usually responses to SEC staff review.

Deal terms

Est. pre-money$209M

Price / share$4.50

Shares offered11,111,111

Estimated, not stated: $4.50 × 46,439,105 securities outstanding.

Offering details

Target—

Max$50,000,000

Min investment—

OpenedJul 26, 2023

Deadline—

Days active1,172

Links & provenance

SEC filing

Source: SEC EDGAR
0001683168-23-005097
Last synced Aug 16, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.